Analyst
Needham & Company
Equibles does not estimate personal net worth.
Serge Belanger is recorded as Analyst at Needham & Company. Serge Belanger has spoken on 4 earnings calls and 3 other investor events across 6 companies, most recently for Cytokinetics Inc on August 6, 2026. Those appearances were for Cytokinetics Inc (CYTK), Polaryx Therapeutics, Inc. (PLYX), Collegium Pharmaceutical, Inc (COLL), Arcutis Biotherapeutics, Inc. (ARQT), Liquidia Corp (LQDA) and 1 other company. The companies whose calls Serge Belanger spoke on are classified in the Healthcare sector.
“As you mentioned, about 300 of the 700 million prescribers in my quarters are due to high volume CMI users. I assume these are also CANZEOS users, so is there any indication at this point on whether these high volume prescribers will continue using both products or eventually they'll adopt just one?”
“I want to welcome everybody this morning to our 25th Annual Healthcare Conference. And for our next presentation, we have the Polarix Therapeutics team with us.”
“I want to welcome everybody this afternoon to Needham's 25th Annual Healthcare Conference. For our next Fireside Chat session, we have Collegium Pharmaceutical with us.”
“I'm one of the health care analysts at Needham. I want to welcome everybody to Needham's 25th annual health care conference. And for our next fireside chat session this morning, we have our Cutis Biotherapeutics with us.”
“First question on the legal front, any new updates or developments that you can share with us? And then secondly, regarding payer access, I think you reported another 85% prescription to patient start conversion.”
Needham & Company
Analyst
Source not stated
CYTK
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
